Melior Discovery
Biopharmaceutical company in Pennsylvania
From Wikipedia, the free encyclopedia
Melior Discovery, Inc. is a private biopharmaceutical company based in Exton, Pennsylvania, USA.
 | |
| Company type | Private company |
|---|---|
| Industry | Biotechnology |
| Founded | 2005 |
| Founder | Andrew Reaume Michael Saporito |
| Headquarters | Exton, Pennsylvania |
| Products | Pharmaceuticals, contract research |
| Website | www |
Products and services
The company specializes in drug repositioning and has established a proprietary phenotypic screening platform that it uses for this purpose. Melior also offers certain contract research organization (CRO) services comprising animal models representing different disease conditions.[citation needed]
The Company has issued press releases disclosing partnerships with Pfizer, Merck & Co., Johnson & Johnson, and AstraZeneca, all citing the use of the company's drug repositioning technology. Melior Discovery has also used its technology to discover its own drug candidates.[citation needed]
History
Melior Discovery was co-founded in 2005 by Dr. Andrew Reaume (President and CEO) and Dr. Michael Saporito (Vice President of Research).[1] Its investors include Cammeby's Capital Group, VenturEast, Osage Ventures, Mid-Atlantic Angel Group, and BioAdvance.[2]
In March 2009, the Food and Drug Administration (FDA) approved the company's Investigational New Drug (IND) application for a type 2 diabetes therapeutic candidate, MLR-1023.[3] In 2013, the company reported a licensing partnership with Bukwang Pharmaceutical Company LTD[4] and the initiation of clinical trials in March 2015.[5] In June 2016, the company reported positive results from their Phase 2a clinical study in diabetic subjects.[6]